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BNP7787 (disodium 2,20-dithio-bis-ethane sulphonate; Tavoceptt) is a novel agent developed to protect against cisplatin (cis-
diammine-dichloroplatinum(II))-associated chronic toxicities. In this study, we determined the recommended dose of BNP7787 when
preceding a fixed dose of cisplatin, the pharmacokinetics (PKs) and the possible reduction of saline hydration. Patients with advanced
solid tumours received BNP7787 in escalating doses of 4.1–41gm
 2 as a 15-min intravenous (i.v.) infusion followed by cisplatin
75mgm
 2 as a 60-min i.v. infusion together with pre- and postcisplatin saline hydration in a volume of 2200ml; cycles were repeated
every 3 weeks. PK was carried out using BNP7787, cisplatin and the combination. Twenty-five patients were enrolled in stage I of the
study to determine the recommended dose of BNP7787. No dose-limiting toxicity was reached. The highest dose level of 41gm
 2
resulted in a low incidence of grade 2 toxicities, being nausea and vomiting, dry mouth or bad taste and i.v. injection site discomfort.
Doses of BNP7787 X18.4gm
 2 did not show a drug interaction between BNP7787 and cisplatin. In stage II of the study, patients
received a fixed dose of BNP7787 of 18.4gm
 2 preceding cisplatin and were entered in prespecified reduced saline hydration steps.
A total of 21 patients in cohorts of six to nine patients received reduced saline hydration of 1600ml (step A), 1000ml (step B) and
500ml (step C). In step C, two out of six evaluable patients experienced grade 1 nephrotoxicity. Cisplatin acute toxicities in all 46
patients were as expected. Only five patients complained of paresthesias grade 1 and six developed slight audiometric changes. Partial
tumour response was observed in four patients and stable disease in 15 patients. In conclusion, BNP7787 was tolerated well up to
doses of 41gm
 2. The recommended dose of 18.4gm
 2 enabled safe reduction of the saline hydration schedule for cisplatin to
1000ml. Further studies will assess whether BNP7787 offers protection against platinum-related late side effects.
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The administration of cisplatin (cis-diammine-dichloroplatinum
(II)), a well known and widely used broad-spectrum cytotoxic
agent, is limited by the occurrence of serious toxicities such as
nephrotoxicity. Several chemoprotective agents have been inves-
tigated in the attempt to ameliorate these side effects and
potentially reduce the need for adequate hydration to prevent
nephrotoxicity.
The utility and safety of an ideal chemoprotective agent include
several considerations: (i) the compound should prevent, delay or
mitigate drug-induced toxicities; (ii) the compound should not add
important toxicities of its own; and (iii) the compound should not
interfere with the antitumour activity. The mechanism of action of
sulphur-containing nucleophiles that have been tested to prevent
cisplatin-induced nephrotoxicity is based on inactivation of highly
reactive monohydrated platinum species at the site of organ
damage, that is, the kidney. Several modulating agents to prevent
nephrotoxicity, such as thiosulphate (Leeuwenkamp et al, 1991),
diethyldithiocarbamate (Gandara et al, 1995; Paredes et al, 1988),
glutathione (Smyth et al, 1997), amifostine (Kemp et al, 1996;
Hartmann et al, 2000) and mesna (Leeuwenkamp et al, 1991;
Hausheer et al, 1998; Boven et al, 2002), have been investigated.
Strong chemical reactivity of thiosulphate, diethyldithiocarbamate
and mesna with cisplatin preclude their clinical usefulness
(Verschraagen et al, 2003b). In phase III clinical trials, glutathione
and amifostine have shown not to interfere with the antitumour
activity of cisplatin (Kemp et al, 1996; Smyth et al, 1997; Hartmann
et al, 2000). The only compound registered for preventing
nephrotoxicity in patients with advanced cancer is amifostine
(Schuchter et al, 2002). The present data do not support its routine
use for prevention of cisplatin-associated neurotoxicity or
ototoxicity (Schuchter et al, 2002). The administration of
amifostine requires close patient monitoring as the compound
can induce symptomatic hypotension in addition to emesis.
BNP7787 (disodium 2,20-dithio-bis-ethane sulphonate; Tavoceptt)
is undergoing development as a novel chemoprotector against
common and serious cisplatin- and paclitaxel-induced toxicities
(Hausheer et al, 1998; Hausheer et al, 2003). In preclinical studies
in rats and dogs, BNP7787 has been shown to protect against
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scisplatin-induced nephrotoxicity as confirmed by histopathology of
kidney tissue. Previously, it has been reported by Ormstad and
Uehara (1982) and Ormstad et al (1983) that BNP7787 is selectively
taken up by the kidneys where it is converted into mesna. We have
recently analysed the pharmacokinetics (PKs) of BNP7787 given at a
dose of 1000mgkg
 1 intravenously (i.v.) in WARD colon tumour-
bearing rats (Verschraagen et al, 2004a). High AUC values of
BNP7787 and mesna were observed specifically in the kidney in
contrast to at least 5.5-fold lower AUC values in the liver and tumour.
In addition, we have shown that several detoxification routes present
in the kidney, such as the endogenous thiols glutathione and
cysteine, the glutaredoxin system as well as the thioredoxin system,
were able to reduce BNP7787 to mesna (Verschraagen et al, 2004b).
These findings may explain the substantial reductive capacity of the
kidney, because of which mesna generated from BNP7787 can locally
inactivate toxic monohydrated platinum species.
BNP7787 is the disulphide form of mesna and, therefore, does
not contain a free thiol group that would interfere with the
antitumour effects of cisplatin. Indeed, in preclinical studies in rats
bearing WARD colon tumour as well as in nude mice bearing
OVCAR-3 human ovarian cancer xenografts, it has been shown
that BNP7787 did not reduce the tumour growth inhibition
obtained with cisplatin (Hausheer et al, 1998; Boven et al, 2002).
Moreover, BNP7787 protected against cisplatin-induced side
effects in rats and dogs such as vomiting, myelosuppression and
dose-limiting nephrotoxicity (Hausheer et al, 1998). Considerably
high doses of BNP7787 could be administered i.v. without the
introduction of side effects or lethal toxicity in all of these studies.
Based on the promising preclinical data of BNP7787, a phase I
clinical study was performed in patients with solid tumours treated
with a fixed dose of cisplatin every 3 weeks preceded by BNP7787
in escalating doses. In stage I of the study, PKs were carried out
analysing cisplatin and BNP7787 alone and in combination. After
having established the recommended dose of BNP7787, possible
reduction of the saline hydration schedule of cisplatin was assessed
in stage II of the study.
PATIENTS AND METHODS
Eligibility criteria
For study entry, patients were required to have a histologically or
cytologically documented solid malignancy refractory to standard
treatment, could not receive standard treatment or standard
treatment was not available and were not previously treated with
cisplatin or carboplatin. Eligibility criteria were as commonly used
and included, among others, a serum creatinine p120mmoll
 1
and a calculated 24-h creatinine clearance of X60mlmin
 1.
Creatinine clearance was calculated from a 24-h urine collection,
but the Cockcroft–Gault formula was used in cases where the 24-h
urine collection was incomplete. All patients provided written
informed consent according to institutional ethical guidelines. The
study was approved by the scientific and ethical review committee
of the institution.
Trial design
BNP7787 was supplied in glass vials containing 1.0, 2.0, 5.0 or 10g
of compound presented as a sterile, white powder. The agent was
reconstituted by adding sterile water for injection to obtain a final
concentration of 100–250mgml
 1. In patients where reconstituted
BNP7787 caused local irritation at the site of infusion due to low
pH (pH 6.7), NaHCO3 8.4% was added in a volume of 0.1–
0.2mlg
 1 BNP7787 (dose levels 4.1–18.4gm
 2) to subsequent
cycles. NaHCO3 8.4% was increased to 0.4mlg
 1 BNP7787 and was
admixed with the formulation routinely at higher doses of
BNP7787. During the study, BNP7787 formulation was changed
to a lyophilised presentation that did not cause local transient
discomfort. Therefore, in stage II of the study, the addition of
NaHCO3 8.4% to the BNP7787 solution was omitted. After
calculation of the volume of dissolved BNP7787 plus or minus
NaHCO3, sterile NaCl 0.9% was added to a total volume of 300ml.
Cisplatin (platosin 1.0mgml
 1; Pharmachemie BV, Haarlem, The
Netherlands) was added to sterile NaCl 0.9% to a total volume of
180ml.
The infusion schedule of BNP7787 and/or cisplatin for stage I of
the study is shown in Table 1. Patients were treated with cisplatin
75mgm
 2 i.v. as a standard dose every 3 weeks. All patients
received BNP7787 alone 1 week before the coadministration with
cisplatin using the same administration schedule as described in
Table 1. The prespecified BNP7787 starting dose was 4.1gm
 2.
This starting dose was based on the analysis and calculation of a
BNP7787: cisplatin 50:1 molar ratio that was required for partial
cisplatin nephroprotection in rats (Hausheer et al, 1998). This dose
represented 17% of the maximum tested dose in rats and 10.2% of
that tested in Beagle dogs; these maximum tested doses were
neither lethal nor toxic. Dose escalation steps of BNP7787 in
cohorts of three patients each according to the protocol were 8.2,
12.3, 18.4, 27.6 and 41.0gm
 2. The dose of 41.0gm
 2 was
considered to be the end point dose, since the molar ratio of
BNP7787:cisplatin of 503:1 would be far in excess to that required
for protection in rats. Reduced dose escalation steps were to be
taken in case of grade 2 BNP7787 toxicity, excluding suboptimally
treated nausea and vomiting. Dose-limiting toxicity felt to be
directly due to the study drug during stage I was defined as grade 4
neutropenia and any other manifestation of grade 3–4 toxicity,
except for suboptimally treated nausea and vomiting. In case of
dose-limiting toxicity in one patient at any dose level, a maximum
of three additional patients would be treated. The maximum-
tolerated dose was defined as the highest dose at which level only
one out of six patients was allowed dose-limiting toxicity due to
the study drug. In the event that a dose of 41.0gm
 2 would be
reached, a total of six patients were to be studied.
Systematic reduction of saline hydration for a 75mgm
 2 dose of
cisplatin preceded by a fixed dose of 18.4gm
 2 of BNP7787 was
studied in steps A–D in stage II of the study. The infusion
schedules are listed in Table 2. The number of patients per reduced
hydration step was six. Only one out of six patients was allowed
with grade 1 nephrotoxicity (creatinine upper normal value of the
institution was 110mmoll
 1) or creatinine clearance o60mlmin
 1
on the day of the next cycle. If more than one out of six patients
experienced grade 1 nephrotoxicity, the previous hydration step
was considered the safe reduced hydration regimen.
Standard antiemetic prophylaxis was given to all patients
receiving cisplatin and consisted of ondansetron 8mg i.v. and
dexamethasone 8mg i.v. 30min prior to cisplatin. In case of
persistent nausea and vomiting following treatment, the antiemetic
regimen was repeated after 12h. When diuresis was less than
Table 1 Infusion schedule of BNP7787 and/or cisplatin in stage I of the
study
Time period
(min) Volume (ml) Contents of the infusion fluid
90 1000 NaCl 0.9%, 20mmol KCl, 2g MgSO4
10 100 Mannitol 20%
15 300 BNP7787 (by syringe pump if PK)
60 180 Cisplatin 75mg/m
2 (by syringe pump if PK)
90 1000 NaCl 0.9%, 20mmol KCl, 2g MgSO4
10 100 Mannitol 20% (+furosemide 10mg)
a
BNP7787¼disodium 2,20-dithio-bis-ethane sulphonate; cisplatin¼cis-diammine-
dichloroplatinum(II); PK¼pharmacokinetics.
aAt the end of the infusion over a total
period of 4h diuresis should be at least 1000ml; if not, furosemide 10mg i.v. should
be administered.
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s1000ml over a total period of 4h of the infusion schedule in stage
I, patients received mannitol 20% and furosemide 10mg i.v.
(Table 1). In stage II of the study, no specific attention was paid to
diuresis control. In case of excessive vomiting, the patients would
continue i.v. infusion of NaCl 0.9% 500ml every 6h regardless of
the stage of the protocol.
Toxicity and response
Before the start of treatment, a medical history was taken and
patients underwent a complete physical examination, including
assessment of height, weight, blood pressure, temperature and
performance status. The pretreatment evaluation also included a
full blood cell count, a biochemical screening profile, coagulation
tests, urinalysis, calculated creatinine clearance, audiogram and
tumour measurements. All toxicities were assessed in accordance
with the NCl Common Toxicity Criteria (original version). During
the study, weekly full blood counts and serum creatinine
measurements were performed. Before each treatment cycle, an
interval history, a physical examination, the biochemical screening
profile, coagulation tests, a creatinine clearance assessment,
urinalysis and tumour measurements were performed. In case a
CT scan was required for assessment of tumour response, this was
carried out every three cycles. A baseline audiogram was required
and a repeat audiogram was performed every three cycles.
Response to treatment was assessed using adequate imaging
techniques to visualise tumour lesions. The ECOG criteria for
tumour response in measurable disease were employed. Patients
with an objective response or stable disease continued treatment
until excessive toxicity or patient’s refusal.
Pharmacokinetics
One patient of each cohort and all patients of the cohort receiving
the highest dose of BNP7787 in stage I of the study were subjected
to PK analysis of plasma BNP7787, mesna, and total platinum,
intact platinum, monohydrated cisplatin and unbound platinum.
An extensive analysis of all PK data is presented in a separate
report (Verschraagen et al, 2003a). A summary is given below.
In patients undergoing PK analysis, cisplatin was given alone,
which was followed by the administration of BNP7787 alone 2
weeks later. A week after BNP7787 alone, the patient received the
BNP7787 plus cisplatin combination. The infusion schedule, also
of BNP7787 alone, was given according to Table 1 and drugs were
delivered using syringe pumps.
For the high-performance liquid chromatography (HPLC)
analysis of BNP7787 and its metabolite mesna, plasma samples
were collected just before treatment and at 8, 15, 25, 35, 45min and
1, 1.25, 1.75, 2.25, 4.25 and 6.25h after the start of the BNP7787
infusion. Samples were deproteinised and the total amount of
mesna and BNP7787 was measured by HPLC (with electrochemical
detection) according to the method described (James et al, 1987;
El-Yazigi et al, 1997; Verschraagen et al, 2001). For the analysis of
total platinum, intact cisplatin, monohydrated cisplatin and
unbound platinum, plasma samples were collected just before
treatment and at 0.5, 1, 1.5, 2, 3, 4 and 6h after the start of the
cisplatin infusion. Total platinum in plasma and unbound
platinum in deproteinised plasma were measured by flameless
atomic absorption spectrometry (FAAS) (Verschraagen et al,
2003a). Intact cisplatin and monohydrated cisplatin fractions in
deproteinised plasma were separated by HPLC, and subsequently,
the platinum contents were measured by FAAS (Verschraagen
et al, 2002).
Pharmacokinetic parameters, that is, final half-life (t1/2), area
under the concentration–time curve over time interval 0 t
(AUC
0 t), area under the curve to infinity (AUC
N), mean
residence time (MRT), total body clearance (Cl) and steady-state
volume of distribution (Vss) were determined by noncompart-
mental analysis using the validated PK data analysis program
WinNonLin Standard Edition version 1.5 (Pharsight Corporation,
Mountain View, USA). The maximum plasma concentration
(Cmax) and time of observed maximum concentration (tmax) were
obtained from the concentration–time data. To compare the Cl
and Vss values between patients, the values were normalised for
body surface area (1.73m
2) and for body weight (kg), respectively.
RESULTS
Demographics
Twenty-five patients were enrolled in stage I of this phase I study.
Patient characteristics are described in Table 3. One patient with
lung cancer and a previous response to carboplatin and paclitaxel
was allowed to enter the trial. All patients received at least two
cycles containing cisplatin. A concern that potential mesna levels
would be unacceptably high and lead to toxicity at doses of
BNP7787 418.4gm
 2 resulted in inclusion of two new cohorts:
three patients received BNP7787 23.0gm
 2 and one patient
received BNP7787 34.5gm
 2. At the BNP7787 41.0gm
 2 dose
level, a total of six patients were treated.
A total of 21 patients were enrolled in stage II of the study.
Patient characteristics are listed in Table 3. Reduced saline
hydration steps A and B included six patients each. Nine patients
entered step C. Three patients in step C were replaced as these were
considered not to be evaluable for nephrotoxicity for the following
reasons: one patient had rapidly progressive disease after cycle 1,
one patient had a baseline creatinine value (109mmoll
 1) that was
considerable higher than that measured after cycle 3 (72mmoll
 1)
and one patient had variable creatinine values due to periods of
poor fluid intake.
Side effects from BNP7787
Initially, BNP7787 was supplied as a sterile powder. Most patients
received treatment via a peripheral vein and occasionally
complained about discomfort at the site of BNP7787 infusion
Table 2 Infusion schedule of BNP7787 and cisplatin in stage II of the
study
Time period
(min) Volume (ml) Contents of the infusion fluid
Step A
90 1000 NaCl 0.9%, 20mmol KCl, 2g MgSO4
10 100 Mannitol 20%
15 300 BNP7787 18.4mg/m
2
60 180 Cisplatin 75mg/m
2
30 500 NaCl 0.9%, 10mmol KCl, 1g MgSO4
Step B
60 500 NaCl 0.9%
15 300 BNP7787 18.4 g/m
2
60 180 Cisplatin 75mg/m
2
30 500 NaCl 0.9%
Step C
30 500 NaCl 0.9%
15 300 BNP7787 18.4 g/m
2
60 180 Cisplatin 75mg/m
2
Step D
15 300 BNP7787 18.4 g/m
2
60 180 Cisplatin 75mg/m
2
BNP7787¼disodium 2,20-dithio-bis-ethane sulphonate; cisplatin¼cis-diammine-
dichloroplatinum(II).
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s(Table 4). The local i.v. site discomfort subsided promptly after
completion of the BNP7787 infusion or by extending the infusion
time from 15 to 30min. BNP7787 did not cause thrombophlebitis.
The local discomfort was believed to be due to the low pH (pH 6.7)
of BNP7787 powder dissolved in water and diluted in NaCl 0.9%.
The addition of NaHCO3 8.4% alleviated this symptom promptly
as well as switching to a lyophilisation process for the formulation
of BNP7787 during the study. At higher doses of BNP7787 to which
NaHCO3 was added, occasionally a patient complained about
transient discomfort at the site of infusion. At the highest dose of
BNP7787 of 41.0gm
 2, regardless of the addition of NaHCO3,i n
eight of 26 cycles local discomfort grade 1 and in two cycles grade
2 (one patient) was reported.
Side effects other than transient local discomfort from BNP7787
occurred occasionally at doses of 18.4–34.5gm
 2 and were rather
mild (Table 4). Also, when present, complaints were reported in
only one cycle and disappeared immediately after the end of the
infusion. Most frequent toxicities consisted of hot flushes or a
warm feeling, dry mouth or bad taste, dizziness and headache. One
patient experienced nausea grade 2 and abdominal pain grade 2 in
cycle 1, but had no complaints in cycle 2. At the highest dose of
BNP7787 of 41.0gm
 2 administered to six patients, side effects
were more prominent. The incidence and grade of nausea and
vomiting increased as well, but did not exceed grade 2. Thus, the
maximum-tolerated dose of BNP7787 was not established in this
study. The BNP7787 18.4gm
 2 dose was recommended for further
clinical studies, since (i) this dose was tolerated well, (ii) a
BNP7787:cisplatin molar ratio of 225:1 was considered to achieve
sufficient chemoprotection, since a 50:1 molar ratio already
partially protected nephrotoxicity in rats, and (iii) there was no
evidence of a drug interaction (see below).
Based on the use of the lyophilised formulation in the course of
the study, it was determined that BNP7787 18.4gm
 2 could be
given without NaHCO3 in stage II of the study. Only in one cycle of
a patient who received four cycles local i.v. site discomfort grade 1
necessitated prolongation of the BNP7787 infusion up to 30min
(Table 4). All other cycles were not complicated by local irritation.
In stage II of the study, other side effects from BNP7787 were
absent, except for one cycle in which transient hot flushes were
reported.
Side effects from cisplatin
A total of 45 patients in stages I and II of the study could be
evaluated for cisplatin-induced side effects. Of these patients, three
received one cycle only; the median number of cycles administered
was 3 (range 1–9). Most common acute toxicities recorded were
nausea, vomiting and fatigue (Table 5). Five patients suffered from
grade 3 nausea, two patients from grade 3 vomiting and five
patients from grade 3 fatigue. Other toxicities grade 2 encountered
were a change in taste (one patient), anorexia (four patients) and
weight loss (two patients). Myelosuppression, not exceeding grade
2, more often occurred in patients treated with X4 cycles of
cisplatin.
Out of 16 patients treated with X4 cycles of cisplatin
(X300mgm
 2 cumulative cisplatin dose), five complained of
paresthesias grade 1. At the lowest dose level of BNP7787 4.1gm
 2,
there were two patients with paresthesias: in one patient this
started at cycle 5, but symptoms did not worsen within the 9-cycle
period of treatment, and the other patient had neurological
complaints at the 8th and last cycle. One patient on BNP7787
12.3gm
 2 dose level had paresthesias at the 6th and last cycle. At
the BNP7787 23gm
 2 dose level, one patient had complaints at
cycle 6 out of a total of seven cycles. A last patient at the 41.0gm
 2
BNP7787 dose level had paresthesias recorded in the 9th and last
cycle. Another five patients who received X6 cycles of cisplatin
had no subjective peripheral neurotoxicity.
All 16 patients treated with X4 cycles of cisplatin had a repeat
audiogram and five out of eight patients treated with X6 cycles
had a second repeat audiogram. In six patients, slight hearing loss
was recorded after cycle 3 (one patient), cycle 4 (two patients),
cycle 5 (two patients) and after cycle 6 (one patient). Four of these
patients had occasional tinnitus from cycle 2 (one patient), cycle 4
(two patients) and cycle 7 (one patient) onwards. Three other
patients complained of occasional tinnitus after one cycle (one
patient) and after two cycles (two patients) of cisplatin without
changes on the audiogram, but were not treated further.
Table 3 Patient characteristics
Stage I Stage II
Total no. of patients 25 21
Male/female 14/11 14/7
Age (years)
Median 53 58
Range 37–64 42–70
ECOG performance status
Median 1 1
Range 0–2 0–2
Prior therapy
Chemotherapy 14 8
Radiotherapy 3 5
Chemotherapy+radiotherapy 2 5
None 6 3
Tumour type
Colorectal 8 7
Lung 3
Melanoma 2 1
Mesothelioma 2
Stomach 1 1
Bile duct 2 1
Pancreas 1 1
Head and neck 2 4
Breast 1
Kidney 1
Unknown primary 2 1
Other 2 3
ECOG¼Eastern Cooperative Oncology Group.
Table 4 Number of cycles with grade 1 side effects from BNP7787
Stage I Stage I Stage II
4.1–34.5g/m
2 41.0g/m
2 18.4g/m
2
Side effect (78 cycles) (26 cycles) (62 cycles)
Hot flushes or warm feeling 2 10 1
Dry mouth or bad taste 2 6 (1 grade 2)
Headache 1 10
Dizziness 2 11
Hypotension 2
Perspiration 1
Myalgia 1
Nausea 1 (1 grade 2) 7 (5 grade 2)
Vomiting 8 (4 grade 2)
Abdominal pain 1 (1 grade 2)
Vigors 1
Fatigue 2
Pain chest 1
Paresthesias 1
Local i.v. site discomfort 9 (4 grade 2) 10 (2 grade 2) 1
BNP7787¼disodium 2,20-dithio-bis-ethane sulphonate; i.v.¼intravenous.
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and eight were treated with X6 cycles cisplatin preceded by
BNP7787. Only one patient at the BNP7787 4.1gm
 2 level showed
an increase in creatinine grade 1 at cycle 6. Nephrotoxicity in this
patient did not deteriorate further during the 9-cycle treatment
period.
Reduction of the hydration schedule
In stage II of the study, four decremental steps were prespecified
to evaluate the nephroprotective effect of BNP7787 18.4gm
 2
prior to cisplatin using a reduced volume of saline hydration
that is otherwise required for cisplatin administration. None of
the patients continued additional 500ml NaCl 0.9% every 6h for
excessive vomiting.
Figure 1 step A depicts the creatinine values measured in the
first two cycles of cisplatin given with hydration according to step
A. Two out of six patients received only one cycle due to rapidly
progressive disease. The maximum number of cycles administered
to patients in cohort step A was 3. No patient experienced
nephrotoxicity grade 1 in cohort A. In cohort B, there was no
evidence of cisplatin nephrotoxicity on the day starting cycle 2 or 3
(Figure 1 step B). One patient, however, had a baseline creatinine
value of 85mmoll
 1, which showed a transient increase to
101mmoll
 1. Owing to rapidly progressive disease, this patient
discontinued treatment. Two patients who received four and six
cycles, respectively, according to hydration step B did not show
evidence of cisplatin-induced renal toxicity.
Cohort C consisted of nine patients because of replacement of
one patient who had rapidly progressive disease and two patients
who were not evaluable for cisplatin-induced nephrotoxicity (see
demographics). All six evaluable patients received at least two
cycles, of which four showed a transient increase in creatinine up
to grade 1 in between cycles. Two patients experienced nephro-
toxicity grade 1 at the end of the first (creatinine 123mmoll
 1) and
the second cycle (creatinine clearance 58.5mlmin
 1), respectively
(Figure 1 step C). One of these patients was further hydrated
according to step B from cycles 2–5; baseline creatinine of
96mmoll
 1 increased to 128mmoll
 1 by the end of cycle 5, but
recovered to 97–105mmoll
 1 in the week thereafter. The other
patient was hydrated according to step B from cycle 3 and
according to stage I of the study from cycles 4–8; baseline
creatinine of 91mmoll
 1 increased to 126mmoll
 1 by the end of
cycle 8 and recovered to 109mmoll
 1 within 3 weeks. One other
patient received six cycles in which the transient increase in
creatinine in between cycles reached grade 1 at the start of cycle 6.
Thus, in cohort step C, two out of six patients reached the stopping
rule of step-wise reduction in saline hydration in the first two
treatment cycles. Therefore, step D was cancelled.
Tumour response
Most patients who entered the study had an advanced solid
malignancy for which cisplatin is not a standard treatment, except
three patients with lung cancer and six patients with head-and-
neck cancer (Table 3). A partial tumour response was noted in four
Table 5 Common acute side effects from cisplatin at various dose levels of BNP7787 and hydration schedules
BNP7787
(mg/m
2)
Hydration
schedule
No. of
patients
No. of
cycles
Nausea Vomiting Fatigue Leucopenia Neutropenia Thrombopenia
123123123123123123
4.1 Stage I 3 26 111120201120020020
8.2 Stage I 3 9 300100001000000000
12.3 Stage I 3 10 300210010000000000
18.4 Stage I 3 7 120200000000000200
23.0 Stage I 3 15 120110020020200000
27.6 Stage I 3 9 021110010100000100
34.5 Stage I 1 2 100000010000000000
41.0 Stage I 6 26 330240030210110100
18.4 II – step A 6 12 231230112100100200
18.4 II – step B 6 19 121012030020110200
18.4 II – step C 8 31 141250221100000100
BNP7787¼disodium 2,20-dithio-bis-ethane sulphonate; cisplatin¼cis-diammine-dichloroplatinum(II).
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Figure 1 Creatinine values of patients treated with cisplatin 75mgm
 2
preceded by BNP7787 18.4gm
 2 every 3 weeks and saline hydration
schedules according to steps A, B and C (Table 2). Day 21 and day 42
represent the start of cycle 2 and cycle 3, respectively. Dotted line: upper
normal value of the institution. Each symbol represents one patient.
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spatients, one patient with melanoma, one with head-and-neck
cancer, one with two adenocarcinoma primaries originating from
lung and breast and one with a bile duct cancer. Stable disease was
noted in 15 patients of the following tumour types: colorectal
cancer (three patients), adenocarcinoma of unknown primary
(three patients), head-and-neck cancer (four patients), and lung
cancer, chondrosarcoma, mesothelioma, bile duct cancer and renal
cell cancer (one patient each).
Pharmacokinetics
Detailed analysis of PKs of BNP7787 and cisplatin has been
reported elsewhere (Verschraagen et al, 2003a) and can be
summarised as follows. Linear PKs was observed for both the
AUC
N and Cmax of BNP7787 and mesna enabling normalisation of
values for the dose. The mean normalised AUC
N of mesna was
approximately 8% of the normalised AUC
N of BNP7787. The
mean t1/2 of BNP7787 in plasma was 1.4h, while that of mesna was
2.7h. MRT of mesna was approximately two-fold longer than
that of BNP7787 (ie 4.5 and 1.9h, respectively). The Vss and Cl
of BNP7787 were approximately 0.26lkg
 1 and 9.2lh
 11.73m
 2,
respectively. The BNP7787 and mesna curves after the BNP7787
administration were similar to the curves obtained after BNP7787
followed by cisplatin. Semilogarithmic plasma concentration–time
plots for BNP7787 and mesna observed in the patient who received
18.4gm
 2 BNP7787 alone and in combination with 75mgm
 2
cisplatin are shown in Figure 2.
The concentration–time curves of total platinum, unbound
platinum, monohydrated cisplatin and intact cisplatin were similar
after cisplatin administration or preceded by BNP7787. Only in
patients sampled at a dose of 4.1, 8.2 and 12.3gm
 2, BNP7787
administration showed a slight tendency to lower the plasma
concentrations of intact cisplatin. BNP7787 did not influence the
intact cisplatin concentrations at doses of X18.4gm
 2. Semiloga-
rithmic plasma concentration–time plots for total platinum,
unbound platinum, monohydrated cisplatin and intact cisplatin
observed in the patient who received 75mgm
 2 cisplatin alone
and in combination with 18.4gm
 2 BNP7787 are shown in
Figure 3.
DISCUSSION
We performed a phase I study to explore the safety, the maximum-
tolerated dose and the recommended dose of i.v. BNP7787 when
preceding a fixed dose of cisplatin. Side effects attributable to the
study drug were minor and included occasional discomfort at the
site of the infusion and a low incidence of nausea and vomiting,
dry mouth or bad taste, not exceeding grade 2. BNP7787-related
toxicities disappeared promptly after the end of the infusion. Dose-
limiting toxicity was not reached, since a dose of 41.0gm
 2 of
BNP7787 was considered as the end point of the study.
Pharmacokinetics at doses of BNP7787 X18.4gm
 2 did not show
the presence of a drug interaction between BNP7787 and cisplatin
(Verschraagen et al, 2003a).
BNP7787 has been developed specifically as a protector against
late side effects from cisplatin such as nephrotoxicity. In stage I of
the study, a total of 11 patients received X4 cycles and eight were
treated with X6 cycles cisplatin 75mgm
 2 i.v. preceded by
BNP7787. Only one patient at the lowest BNP7787 level of 4.1gm
 2
experienced nephrotoxicity grade 1 that did not progress within
the period of nine treatment cycles given (675mgm
 2 cisplatin
total dose). From literature data, it is expected that the incidence
and the severity of nephrotoxicity rapidly increases at a cumulative
dose of cisplatin of X450mgm
 2. As an example, the incidence of
nephrotoxicity grades 1–3 was 82% in ovarian cancer patients
treated with six to 12 cycles of cisplatin 75mgm
 2 plus cyclophos-
phamide 750mgm
 2 every 3 weeks (Neijt et al, 1987). The same
schedule given for a maximum of six cycles in a similar patient
population was reported to induce grade 1–4 nephrotoxicity in
only 7% of patients (McGuire et al, 1996). Cisplatin 80mgm
 2 day
2 plus gemcitabine 1200mgm
 2 days 1 and 8 given every 3 weeks
up to six cycles to patients with advanced non-small-cell lung
cancer induced renal side effects grades 1–4 in 6.1% of patients
(Mazzanti et al, 2003). Although the number of patients treated
with cisplatin at a cumulative dose X450mgm
 2 according to
stage I of our study was small, the absence of nephrotoxicity when
given concurrently with BNP7787 X18.4gm
 2, being a molar ratio
of 225:1, may suggest some degree of nephroprotection.
At the time of initial introduction of cisplatin for clinical use,
the optimal single dose was 15–20mgm
 2 given every 3 weeks
without hydration (Prestayko et al, 1979). The incidence of
nephrotoxicity was 32% in subsequent phase II studies. Since then,
the incidence and severity of renal toxicity has been substantially
reduced by pre- and posthydration saline infusions up to a volume
of 4000ml and addition of mannitol and furosemide. The
disadvantage of hyperhydration for patients is the overnight stay
in the clinic as the duration of the infusion may be as long as 24h
and the additional costs for monitoring and care. Furthermore,
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Figure 2 Semilogarithmic plasma concentration–time plots of BNP7787
(K, J) and mesna (m, D) of the patient who received a 15-min infusion
of 18.4gm
 2 BNP7787 alone (closed symbols and solid line) and in
combination with 1-h i.v. infusion of 75mgm
 2 cisplatin (open symbols and
dotted line).
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Figure 3 Semilogarithmic plasma AUCs of total platinum (m, D),
unbound platinum (K, J) intact cisplatin (’, &) and monohydrated
cisplatin (E, B) of the patient who received a 1-h i.v. infusion of
75mgm
 2 cisplatin alone (closed symbols and solid line) and in
combination with a 15-min i.v. infusion of 18.4gm
 2 BNP7787 (open
symbols and dotted line).
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spatients with chronic heart failure or unstable cardiac condition
may not receive hyperhydration. In stage II of our study in which
cisplatin 75mgm
 2 was preceded by BNP7787 18.4gm
 2, the
hydration schedule could be reduced to a total volume of 1000ml
given over a period of less than 3h (step B).
Five of 16 patients on X4 treatment cycles in stages I and II of
the study experienced paresthesias grade 1. The incidence and
severity of cisplatin-induced neuropathy largely depends on the
cumulative dose, the onset of symptoms being seen at a total dose
of cisplatin 225–450mgm
 2 (Cavaletti et al, 1997). In the ovarian
cancer patients treated with cisplatin 75mgm
 2 plus cyclopho-
sphamide 750mgm
 2 every 3 weeks for six to 12 cycles, the
incidence of peripheral neuropathy grades 1–3 was 46% (Neijt
et al, 1987), and when given for only six cycles, this was grades 1–4
in 21% of patients (McGuire et al, 1996). In non-small-cell lung
cancer patients treated with cisplatin 80mgm
 2 day 2 plus
gemcitabine 1200mgm
 2 days 1 and 8 every 3 weeks up to six
cycles, the incidence of peripheral neuropathy grades 1–4 was
12.9% (Mazzanti et al, 2003). The cumulative dose of cisplatin at
the start of paresthesias in our study varied between 375 and
675mgm
 2, and notably none exceeded grade 1. It should be
emphasised that three out of five patients with neurological
complaints were treated at the lower dose levels of BNP7787 4.1–
12.3gm
 2. Thus, the low incidence and low grade of paresthesias
induced by cisplatin in patients on X4 cycles of cisplatin in our
study suggests that BNP7787 has a role in the protection against
cisplatin-induced neurotoxicity. Of interest, in two other phase I
trials, BNP7787 administration substantially prevented and
mitigated the severity of paclitaxel-induced neurotoxicity (Haus-
heer et al, 2003) as well as cisplatin-induced neurotoxicity (FH
Hausheer, unpublished data).
Long-term use of cisplatin can cause ototoxicity. Tinnitus may
occur as early as after the first cycle (Cavaletti et al, 1997). After
the third 3-weekly cycle of cisplatin 75mgm
 2 plus cyclopho-
sphamide 750mgm
 2 in the study by Cavaletti et al (1997),
hearing loss was detected in the 8000-Hz frequency range on the
audiogram in 13 out of 19 ovarian cancer patients. Deterioration of
hearing loss was evident in 15 out of their 17 patients examined
after six cycles. All 16 patients in our study treated with X4 cycles
of cisplatin had a repeat audiogram. In six patients, slight hearing
loss was recorded, and four of these patients complained of
occasional tinnitis. Since five out of eight patients treated with X6
cycles had a second repeat audiogram, no definitive conclusion can
be drawn on the long-term prevention of this side effect.
In conclusion, BNP7787 preceding cisplatin was tolerated very
well. Since a low number of patients treated with cisplatin
X300mgm
 2 suffered from nephrotoxicity and neurotoxicity
not exceeding grade 1, BNP7787 might protect against these
cisplatin-induced toxicities. BNP7787 at a dose of 18.4gm
 2 may
enable cisplatin infusion with drastically reduced saline hydration
(1000ml of fluid) in the outpatient clinic. BNP7787 does not
appear to interfere with the antitumour activity of cisplatin, since
several objective responses were observed in this phase I trial.
Currently, phase III trials are underway to determine the
usefulness of BNP7787 in the prevention of paclitaxel- and
cisplatin-associated neurotoxicity without reduction of the anti-
tumour effects.
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